Femasys Inc. (FEMY) Stock Analysis

Why this analysis is different

• A sector-relative MoonshotScore — five pillars (business quality, financial safety, valuation, growth durability, momentum) re-ranked nightly against the full universe of US-listed common stocks.
• An AI Council read across up to eight perspectives — value, macro, quantitative, and momentum lenses — that shows where they disagree instead of averaging the tension away.
• Figures come straight from FMP and Yahoo Finance filings data. The AI writes the narrative around the numbers — it never edits the numbers.

Femasys Inc. (FEMY) Healthcare & Pipeline Overview

Femasys Inc. is a biomedical company focused on the women's healthcare market, providing permanent birth control solutions, artificial insemination products, and diagnostic devices. With a focus on non-surgical technologies, Femasys aims to address unmet needs in reproductive health for obstetrics-gynecological physicians and women's healthcare providers.

What Is the Investment Thesis for FEMY?

Femasys operates in the women's healthcare market, focusing on reproductive health solutions. The company's growth potential hinges on the successful commercialization and adoption of its product portfolio, including FemBloc, FemaSeed, and FemVue. With a market capitalization of $8.27M and a negative profit margin of -521.8%, the company's financial performance is currently challenged. However, a gross margin of 50.4% indicates potential profitability with increased sales and reduced operating expenses. Upcoming catalysts include regulatory approvals and expanded market penetration. Key risks include competition, market acceptance of new technologies, and the company's ability to secure additional funding. The high beta of -2.28 suggests high volatility relative to the market.

Based on FMP financials and quantitative analysis

FEMY Key Highlights

Market Cap of $8.27M reflects the company's small size and growth stage.

• Gross Margin of 50.4% indicates potential for profitability as revenue scales.
• Profit Margin of -521.8% highlights significant operational challenges and ongoing investments in R&D and commercialization.
• Beta of -2.28 suggests the stock price moves inversely to the market, potentially offering diversification benefits.
• Focus on women's healthcare addresses a large and growing market with unmet needs.

Who Are FEMY's Competitors?

FEMY is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.

AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance

What Are FEMY's Key Strengths?

Innovative product portfolio addressing unmet needs in women's healthcare.

• Proprietary technologies and patented solutions.
• Focus on non-surgical and less invasive procedures.
• Experienced management team with expertise in medical device development and commercialization.

What Are FEMY's Weaknesses?

Limited financial resources and reliance on external funding.

• Negative profit margins and ongoing operating losses.
• Small market capitalization and limited trading volume.
• Dependence on regulatory approvals for key product candidates.

What Could Drive FEMY Stock Higher?

Regulatory approval of FemBloc in the United States.

• Expansion of FemVue sales into new international markets.
• Clinical trial results for FemaSeed demonstrating improved pregnancy rates.
• Development and commercialization of FemEMB for uterine cancer detection.

What Are the Key Risks for FEMY?

Financial-distress signal — its Altman Z-Score of -18.59 sits in the distress zone (elevated bankruptcy risk).

• Weak fundamentals — a Piotroski F-Score of 1/9 flags soft profitability, leverage or efficiency.
• Competition from established medical device companies with greater resources.
• Regulatory delays or denials for key product candidates.
• Dependence on external funding to support operations and R&D.
• Market acceptance of new technologies and procedures.
• Product liability claims related to medical devices.

What Are the Growth Opportunities for FEMY?

• Expansion of FemVue Market: Femasys has the opportunity to expand the market reach of FemVue, its saline-air device used in hysterosonography. By targeting new geographies and increasing adoption among obstetrics-gynecological physicians, Femasys can drive revenue growth. The global hysterosonography market is projected to reach $1.2 billion by 2028, offering a substantial opportunity for Femasys to increase its market share. Timeline: Ongoing.
• Commercialization of FemaSeed: FemaSeed, Femasys's artificial insemination solution, represents a significant growth opportunity. By demonstrating improved pregnancy rates compared to traditional methods, Femasys can capture a share of the artificial insemination market. The global artificial insemination market is estimated at $2.5 billion, with a projected growth rate of 6% annually. Timeline: 2027-2028.
• Regulatory Approval and Launch of FemBloc: The successful completion of clinical trials and subsequent regulatory approval of FemBloc, Femasys's permanent birth control solution, would be a major catalyst for growth. FemBloc offers a non-surgical alternative to traditional sterilization procedures, potentially appealing to a large segment of women seeking permanent contraception. The global female sterilization market is valued at $4 billion. Timeline: 2028-2030.
• Development and Commercialization of FemEMB: Femasys's FemEMB product candidate for endometrial sampling in support of uterine cancer detection testing represents a significant growth opportunity. The uterine cancer diagnostics market is growing due to increasing incidence rates and the need for early detection. Successful development and commercialization of FemEMB could provide a new revenue stream for Femasys. The global endometrial biopsy market is estimated at $500 million. Timeline: 2029-2031.
• Strategic Partnerships and Acquisitions: Femasys can pursue strategic partnerships and acquisitions to expand its product portfolio, market reach, and technological capabilities. Collaborating with other companies in the women's healthcare space can accelerate growth and enhance Femasys's competitive position. Potential targets include companies with complementary technologies or established distribution networks. Timeline: Ongoing.

What Opportunities Does FEMY Have?

• Expansion into new geographic markets.
• Strategic partnerships and collaborations with other healthcare companies.
• Increased adoption of minimally invasive procedures.
• Growing awareness of women's reproductive health issues.

What Threats Does FEMY Face?

• Competition from established medical device companies.
• Regulatory hurdles and delays in product approvals.
• Changes in healthcare reimbursement policies.
• Product liability claims and litigation.

What Are FEMY's Competitive Advantages?

• Patented technologies in permanent birth control and artificial insemination.
• First-mover advantage in non-surgical permanent contraception.
• Established relationships with key opinion leaders in women's healthcare.
• Proprietary product designs and manufacturing processes.

What Does FEMY Do?

Femasys Inc., founded in 2004 and based in Suwanee, Georgia, is a biomedical company dedicated to transforming women's healthcare through innovative solutions. The company's primary focus is on developing and commercializing products that address unmet needs in permanent birth control, fertility, and diagnostic testing. Femasys's product portfolio includes FemBloc, a permanent birth control solution; FemChec, a device used in conjunction with FemBloc; FemaSeed, an artificial insemination solution designed to improve pregnancy rates; FemCerv, a biopsy device for endocervical curettage; and FemEMB, a product candidate for endometrial sampling in support of uterine cancer detection testing. Additionally, Femasys commercializes FemVue, a saline-air device used in hysterosonography, in the United States, Europe, Canada, Japan, and internationally. Femasys targets obstetrics-gynecological physicians, related healthcare professionals, women's healthcare provider organizations, and reproductive endocrinologists. The company's commitment to non-surgical product technologies aims to provide women with less invasive and more convenient healthcare options.

What Products and Services Does FEMY Offer?

• Develop permanent birth control solutions (FemBloc and FemChec).
• Offer artificial insemination solutions (FemaSeed).
• Provide biopsy devices for endocervical curettage (FemCerv).
• Develop product candidates for endometrial sampling in support of uterine cancer detection testing (FemEMB).
• Commercialize FemVue saline-air device for hysterosonography.
• Target obstetrics-gynecological physicians and related healthcare professionals.

How Does FEMY Make Money?

• Develop and patent innovative medical devices for women's healthcare.
• Obtain regulatory approvals (e.g., FDA) for commercialization.
• Market and sell products directly to healthcare providers.
• Generate revenue through product sales and licensing agreements.

What Industry Does FEMY Operate In?

Femasys operates within the medical instruments and supplies industry, a segment of the broader healthcare sector. The industry is characterized by technological innovation, stringent regulatory requirements, and evolving patient preferences. The women's healthcare market, in particular, is experiencing growth driven by increasing awareness of reproductive health issues and demand for less invasive procedures. Femasys competes with established medical device companies and specialized players in the fertility and contraception markets. The company's success depends on its ability to differentiate its products through clinical efficacy, safety, and ease of use.

Who Are FEMY's Key Customers?

• Obstetrics-gynecological physicians.
• Related healthcare professionals.
• Women's healthcare provider organizations.
• Reproductive endocrinologists.

Over the past six months, Femasys Inc. insiders filed 26 SEC Form 4 transactions — 0 sales and 26 purchases. On net that is roughly 559K shares acquired (about $636K) — insiders putting money in tends to read as conviction.

Quarterly Financial Performance: Femasys Inc.

Revenue for Femasys Inc. came in at $332K during Q2 FY2026, a 21.9% contraction versus the preceding quarter. The company recorded a net loss of $4.5M, with diluted EPS of $-1.33. Revenue has contracted over three consecutive quarters, which investors in this micro-cap Healthcare stock should monitor closely. Across the four most recent quarters, FEMY averaged $-1.54 in diluted EPS.

FEMY Valuation & Market Position

With a $8.27M market cap, Femasys Inc. sits in the micro-cap segment of the market. Relative to its peer group, FEMY's quantitative score of 18/100 is below the peer average of 42/100.

Key Financial Metrics

Return on assets is -100.0%, showing how much profit it generates from its asset base. A current ratio of 2.14 indicates the company holds enough short-term assets to cover its near-term obligations. Its earnings yield is -128.4%, the inverse of the P/E and a quick read on earnings relative to price.

Femasys Inc.'s Piotroski F-Score is 1/9, a 9-point checklist of profitability, leverage and efficiency — flagging fundamental weakness worth scrutiny. Its Altman Z-Score of -18.59 places it in the distress zone, a signal of elevated financial risk.

Femasys Inc. has beaten Wall Street's EPS estimate in 4 of its last 8 reported quarters — more hits than misses. Reported results have landed about 8.3% above estimates on average.

Company Profile

Femasys Inc. operates in the Medical - Instruments & Supplies industry within the Healthcare sector. It is headquartered in Suwanee, US. The company is led by CEO Kathy Lee-Sepsick. FEMY has traded publicly since 2021.

FEMY Financials

FEMY Latest News

FEMY Analyst Consensus

FEMY MoonshotScore

Latest Femasys Inc. Analysis

Femasys Inc. Healthcare Stock: Key Questions Answered

Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.

Official Resources